FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly treatment reduces bleeding rates and offers convenience via an auto-injector pen.
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for constant intravenous infusions or injections, which are painful as well as inconvenient.
FDA approves first once-weekly drug treatment regimen for hemophilia
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first once-weekly treatment for the disease.
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi,
Pfizer Hemophilia drug Hympavzi Receives USFDA Approval
Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection designed to treat the two primary types of hemophilia, a rare
USFDA gives nod to Pfizer’s drug therapy for patients with Hemophilia
The FDA granted the approval of Hympavzi to Pfizer Inc.
FDA Approves Pfizer's Hympavzi for Hemophilia A, B
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
FDA Approves New treatment option for cutting bleeding in Hemophilia A or B
Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII (FVIII) or IX (FIX), respectively. Patients with these hemophilias
FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
FDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And Adolescents
Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine
Pfizer’s Hympavzi Wins FDA Approval to Treat Hemophilia
Pfizer Inc.’s Hympavzi won US approval to treat hemophilia, a potentially deadly genetic disorder that prevents blood from clotting properly.
hemophilianewstoday1h
What does a minor cut do to someone with hemophilia?
Columnist Alliah Czarielle clears up some common misconceptions about what happens when people with hemophilia have minor cuts or abrasions.
Medpage Today on MSN2d
Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...
devdiscourse1d
Global Health Watch: From Organ Transplants to Avian Flu
A summary of recent health news includes HIV transmission via organ transplants in Brazil, a reconsideration of Eli Lilly's ...
hemophilianewstoday4d
Letting go of the past is hard, but I look forward to my sons’ futures
Now that his sons are grown, columnist Joe MacDonald struggles with letting go of the past and moving on from his role as a caregiver.
2minutemedicine.com4d
Fidanacogene elaparovovec may reduce bleeding in men with hemophilia B
In this randomized controlled trial, fidanacogene elaparovovec therapy significantly reduced the mean annualized rate of ...